AdvanCell Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
93
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$315M
- Investors
-
25
AdvanCell General Information
Description
Operator of radiopharmaceutical therapies intended to treat cancer using targeted alpha-emitting radionuclides. The company offers a proprietary lead-based radionuclide platform, integrated manufacturing, and clinical development capabilities, enabling healthcare providers to access targeted cancer therapies that improve treatment outcomes.
Contact Information
Website
www.advancell.com.auCorporate Office
- 245 Main Street
- Cambridge
- Boston, MA 02142
- United States
Corporate Office
- 245 Main Street
- Cambridge
- Boston, MA 02142
- United States
AdvanCell Timeline
AdvanCell Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series D) | 15-Jul-2026 | $315M | Completed | Clinical Trials - Phase 2 | ||
| 7. Grant | 15-Apr-2025 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC (Series C) | 24-Jun-2025 | Completed | Clinical Trials - Phase 2 | |||
| 5. Early Stage VC | 27-Dec-2023 | Completed | Clinical Trials - Phase 2 | |||
| 4. Grant | 27-Jun-2023 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series B) | 24-Aug-2022 | Completed | Clinical Trials - Phase 2 | |||
| 2. Grant | 15-Dec-2021 | $2.1M | $1.65M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 18-Nov-2020 | $1.65M | $1.65M | Completed | Startup |
AdvanCell Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
AdvanCell Comparisons
Industry
Financing
Details
AdvanCell Competitors (7)
One of AdvanCell’s 7 competitors is Fusion Pharmaceuticals, a Formerly VC-backed company based in Hamilton, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Fusion Pharmaceuticals | Formerly VC-backed | Hamilton, Canada | ||||
| ITM Isotope Technologies Munich | Private Equity-Backed | Munich, Germany | ||||
| RadioMedix | Venture Capital-Backed | Houston, TX | ||||
| Artbio | Venture Capital-Backed | Cambridge, MA | ||||
| RayzeBio | Formerly VC-backed | San Diego, CA |
AdvanCell Patents
AdvanCell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024903000-A0 | Radioisotope generator | Inactive | 19-Sep-2024 | ||
| WO-2026060494-A1 | Radioisotope generator | Pending | 19-Sep-2024 | ||
| WO-2026060494-A8 | Radioisotope generator | Pending | 19-Sep-2024 | ||
| AU-2023902414-A0 | Dosage regimen comprising short-lived radioisotope | Inactive | 31-Jul-2023 | ||
| US-20260284241-A1 | Dosage regimen for short-lived radioisotope | Pending | 31-Jul-2023 | A61K51/088 |
AdvanCell Signals
AdvanCell Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ally Bridge Group | Growth/Expansion | Minority | ||
| Alpha Wave Global | Growth/Expansion | Minority | ||
| Bain Capital | PE/Buyout | Minority | ||
| Eli Lilly and Company Foundation | Limited Partner | Minority | ||
| Eventide Asset Management | Venture Capital | Minority |
AdvanCell FAQs
-
When was AdvanCell founded?
AdvanCell was founded in 2019.
-
Where is AdvanCell headquartered?
AdvanCell is headquartered in Boston, MA.
-
What is the size of AdvanCell?
AdvanCell has 93 total employees.
-
What industry is AdvanCell in?
AdvanCell’s primary industry is Drug Discovery.
-
Is AdvanCell a private or public company?
AdvanCell is a Private company.
-
What is AdvanCell’s current revenue?
The current revenue for AdvanCell is .
-
How much funding has AdvanCell raised over time?
AdvanCell has raised $447M.
-
Who are AdvanCell’s investors?
Ally Bridge Group, Alpha Wave Global, Bain Capital, Eli Lilly and Company Foundation, and Eventide Asset Management are 5 of 25 investors who have invested in AdvanCell.
-
Who are AdvanCell’s competitors?
Fusion Pharmaceuticals, ITM Isotope Technologies Munich, RadioMedix, Artbio, and RayzeBio are some of the 7 competitors of AdvanCell.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process